Project Grant HT9425261E431
Award Date 9/30/26
Completion Date 9/29/30
Dollars Obligated $2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- The Defense Health Agency awarded The University of Texas Southwestern Medical Center $1,699,998 on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to map, characterize, and elucidate the clinical relevance of driver enhancers in lethal prostate cancer. Work is performed in Dallas, Texas, with a period of performance through June 14, 2029. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to...
- The Defense Health Agency awarded the University of Wisconsin – Madison $560,000 on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research into exploiting epigenetic dysregulation for sarcoma treatment. The project will run through October 31, 2029, with work performed in Madison, Wisconsin. This is a Project Grant assistance type supporting basic and applied biomedical research aimed at transforming health care for Service Members and the...
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $2 million under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2026, to support the Prostate Cancer Clinical Trials Consortium. The award funds clinical trial coordination and research activities from September 30, 2026, through September 29, 2030, at Dana-Farber's Boston, Massachusetts location. The Military Medical Research and Development program supports basic, applied, and advanced...
- The Defense Health Agency awarded New York University School of Medicine $750,962 on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate neoadjuvant checkpoint and IL-6 blockade mechanisms of benefit and toxicity. The award supports basic and applied biomedical research with a period of performance through June 14, 2029. Work is performed in New York, New York. The Military Medical Research and Development program funds research to transform...
- The Defense Health Agency awarded The Regents of the University of California, San Francisco $1.199424 million on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research targeting the glucocorticoid receptor to enhance immunotherapy response in metastatic castration-resistant prostate cancer. The award runs through September 29, 2029, with place of performance in San Francisco, California. The Military Medical Research and Development...
- The Defense Health Agency awarded University of California, San Diego $1.65 million on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research targeting oncoembryonic antigens to overcome therapy resistance in patients with triple-negative breast cancer. The award is a Project Grant with a period of performance from May 1, 2026, through April 30, 2029. Work is performed in La Jolla, California. The Military Medical Research and Development...
- The Defense Health Agency awarded the University of California, Los Angeles $528,641 on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate extracellular vesicles as biomarkers in non-Hodgkin lymphoma. The award funds research activities through June 30, 2028, with performance at UCLA's Los Angeles campus. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care...
- The Defense Health Agency (DHA) awarded the University of Washington a $543,285 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on August 1, 2025, with a completion date of July 31, 2028. This award supports research focused on transforming rhabdomyosarcoma treatment through the development and evaluation of new FDA-approved combination therapies. The project will be conducted at the University of Washington's Seattle, Washington location under the...
- The Defense Health Agency awarded the University of California Irvine $140,000 on September 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate SUMO-specific protease 3 as a novel target for improving actinomycin D-based therapies in Wilms tumors. The award is a Project Grant with a period of performance from September 15, 2026, through September 14, 2028. Work is performed in Irvine, California. The Military Medical Research and Development program...
- The Defense Health Agency awarded the University of Wisconsin System $3.087 million on August 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on inhibition of bromodomain containing protein 4 (BRD4) for reversal of idiopathic pulmonary fibrosis. The award funds basic and applied biomedical research intended to transform health care for Service Members and the American public through innovative medical solutions. The University of...